rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Aligos Therapeutics, Inc.

ALGS · Nasdaq

Health CareBiotechnologyNot moving yet

ALGS stood above a rising 150-day average in 6 of the last 52 weekly readings, and has been out of that trend for the last 42 weeks. It is 19.3% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 42
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
31 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders31-2 on the quarter
New · exited6 · 8
Reported value$13.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Deep Track Capital, LPunchanged · filed 14 Aug 2026444,110$2.6M00.0%
Alyeska Investment Group, L.P.unchanged · filed 14 Aug 2026412,000$2.4M00.0%
Sio Capital Management, LLCunchanged · filed 14 Aug 2026327,237$1.9M00.0%
MARSHALL WACE, LLPreduced · filed 13 Aug 2026246,579$1.4M-20,556−7.7%
Woodline Partners LPunchanged · filed 14 Aug 2026177,362$1.0M00.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026175,543$1.0M-2,719−1.5%
BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 202683,055$479K00.0%
HHLR ADVISORS, LTD.unchanged · filed 14 Aug 202676,247$440K00.0%
D. E. Shaw & Co., Inc.added · filed 14 Aug 202666,463$383K+55,485+505.4%
UBS Group AGadded · filed 13 Aug 202659,986$346K+22,925+61.9%
30 Sep 2024 – 30 Jun 2026
253137Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Bridget A. Martell Company insiderDirector · last 25 Jun 20260 · 0
Carole Nuechterlein Company insiderDirector · last 25 Jun 20261 · 0
Heather Preston Company insiderDirector · last 25 Jun 20260 · 0
James Paul Scopa Company insiderDirector · last 25 Jun 20260 · 0
Margarita Chavez Company insiderDirector · last 25 Jun 20260 · 0
Peter Hirth Company insiderDirector · last 25 Jun 20260 · 0
Julian A. Symons Company insiderOfficer · last 9 Mar 20260 · 0
Lawrence Blatt Company insiderPresident and CEO · last 9 Mar 20260 · 0
Lesley Ann Calhoun Company insiderOfficer · last 9 Mar 20260 · 0
Nikhil Aneja Company insiderPrincipal Accounting Officer · last 9 Mar 20260 · 0
Hardean Achneck Company insiderChief Medical Officer · last 8 Oct 20240 · 0
Matthew W. McClure Company insiderChief Medical Officer · last 1 Mar 20240 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-131%
Interest coverFY 2025 · to 31 Dec 2025-39.99×
Share count trendFY 2024 · to 31 Dec 2024-95.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$18.3M
Free cash flowFY 2024 · to 31 Dec 2024−$80.9M

Analyst forecasts

No analyst forecasts yet.